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ABSTRACT
Interleukin-10 Inhibits Cytokine-mediated Synergistic Release of 
Interleukin-6 in Astrocytoma Cells
By
Liliya Vasileva Harizanova
Dr. Bryan L. Spangelo, Examination Committee Chair 
Professor of Chemistry 
University of Nevada, Las Vegas
Astrocytes respond to pro-inflammatory cytokines such as, interleukin-1 
(IL -IP ) and tumor necrosis factor (TNF-a). However, the mechanisms in which IL- 
1(3 and TN F-a mediate cell’s signaling need further investigation.
In previous research, the effects of y-aminobutyric acid (GABA) on IL-1 
and TN F-a signaling pathway were studied. GABA was unable to suppress IkB-o 
degradation and the phosphorylation of p38 by IL-1 (3 and TNF-a. However, it was 
suggested that GABA may be able to inhibit IL-6 release by reducing the rate of 
IkB-o degradation.
Another cytokine, IL-10, which is well known in literature to have anti­
inflammatory effects, is investigated in this study. This study presents IL-10 
effects on the N F-kB and p38 signaling pathways as well as IL-10 inhibition of IL- 
1 and TNF synergistic induction of IL-6 release. The effect of other signaling 
molecules, believed to act as antagonists for p38 activation, were also 
investigated and presented in this study. Previous studies indicate that both IL-1 (3
and TNF-a were able to stimulate the phosphorylation of p38 and the 
degradation of N F-kB inhibitor, IkB-o , with no change in IkB-(3. While IL-10 is 
unable to suppress the phosphorylation of p38 by IL-1 (3 or TN F-a  or degradation 
of IkB-o , inhibitor of N F-kB, it is also suggested that IL-10 may inhibit cytokine- 
mediated synergistic induction of IL-6 in mechanistically similar way to GABA.
Inflammatory cytokines IL-1 (3 and TNF-a have repeatedly shown to 
phosphorylate p38 and activate NF-kB pathway. W e also have shown their 
synergistic effect on release of extracellular IL-6 as well as synergistic increase in 
transcriptional activation of IL-6 mRNA. Anti-inflammatory effects of IL-10, GABA 
and p38 inhibitor SB203580 were also investigated. Experimental results suggest 
that neither IL-10 nor GABA can reverse p38 or NF-kB activation induced by IL- 
ip  and TNF-a. However, they inhibit synergistic release of IL-6 but have no effect 
on IL-6 transcriptional activation. Further, SB203580, inhibitor of p38, decreased 
synergistic m RNA transcript after stimulation with IL -ip  and TNF-a. Our findings 
may postulate that anti-inflammatory molecules such as GABA and IL-10 may 
have similar mode of action supposedly affecting post-translational mechanisms.
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Biochemical Basis of the Central Nervous System  
The biochemical basis of the central nervous system (C N S) must be 
discussed to better understand the nature of Alzheimer’s disease (AD). The CNS  
consists of two types of cells: glia and neurons. Neurons process and transmit 
information by receiving electrochemical impulses and conducting action 
potentials and glia protect and support the neurons. Neurons are organized in 
complex networks to perform the function of the nervous system. Once 
stimulated, they transmit the action potentials to other neurons or effector organs 
(Seely et. al 2000)
Neurons consist of a cell body also called soma and two types of 
processes: dendrites and axons. The soma contains one nucleus which is 
centrally located and contains extensive rough endoplasmic reticulum and Golgi 
apparatus which indicates that this is the main site of protein synthesis. Dendrites 
are cytoplasmic extensions that branch off the neuronal cell body and can be 
stimulated to generate electric currents transmitted to the soma (Seely 2000). 
Axons are the extension of the neuronal soma. They have a constant diameter 
but can vary in length from few millimeters to more than one meter. At their
terminal extensions axons form presynaptic terminais where many small vesicles 
containing neurotransmitters are also present. Action potentials are conducted 
along the axon to the presynaptic terminal, where they can stimulate 
neurotransmitter release.
Neuroglia, on the other hand, are far more numerous than the neurons. 
They provide support, protection and nutrition for neurons. They maintain 
homeostasis, form myelin and participate in signal transduction in the nervous 
system. Glial cells are divided into two subgroups according to their structure and 
function; macroglia and microglia. Oligodendrocytes and astrocytes are 
macroglia. Oligodendrocytes have cytoplasmic extensions that surround and 
wrap around the axons and produce the myelin sheet to protect the neuron, 
except at the nodes of Ravier. Astrocytes possess extensions which spread out 
to occupy areas close to the blood vessels and provide nutrients to the neurons 
nearby. Astrocytes regulate the extracellular composition of brain fluid by 
releasing chemicals which promote the formation of tight junctions between 
endothelial cells and capillaries (Seely 2000). They also regulate the 
concentration of ions and gases and absorb and recycle neurotransmitters. 
Microglia provide the immune defense for the CNS and are specialized 
macrophages found around the brain and blood vessels. They become activated 
in response to injury or inflammation and release cytokines and other signaling 
molecules to repair the damage, phagocytize microorganisms or foreign 
substances.
Neurotransmission
Since glial cells lack an excitable membrane, they cannot transfer 
information. In order to transmit information in the CNS, neurons generate action 
potentials that reach chemical or electrical synapses and finally post synaptic 
receptor proteins. Presynaptic neurons receive signals causing them to release 
either excitatory or inhibitory neurotransmitters. These signaling molecules 
eventually reach and bind receptors on a postsynaptic neuron, causing an action 
potential to be generated. Subsequently, the postsynaptic neuron will propagate 
either excitatory or inhibitory signal.
Neurotransmitter vesicles in the pre-synaptic neuron undergo exocytosis 
in to the synaptic cleft in the wake of an action potential. Once in the synapse, 
the neurotransmitter can then bind the postsynaptic receptors on the 
postsynaptic neuron and continue the propagation of information in the neuronal 
net.
Molecular Pathology of Alzheimer’s disease
Alzheimer’s disease (AD) affects many elderly people and is one of the 
leading causes of death in developed nations. It is a slow but progressive 
terminal disorder that is characterized by deterioration of cognitive and functional 
abilities as well as psychiatric and behavioral symptoms (Yates et.al 2008). It 
was first described by Alois Alzheimer in 1907 as a ‘peculiar disease of the 
cortex’ that affects the CNS (Alzheimer, 1907). Nowadays, a century later, there 
is still no cure for the disease and its cause is still unknown but there are various
hypotheses that have been developed based on experimental data (Behl, 
C.,1999). Pathologists use three main biochemical features to define AD -  
extracellular senile plaques, intracellular tau-rich (i-rich) neurofibrillary tangles 
(NFT) (Glenner and Wong, 1984) and inflammatory processes that contribute to 
deposition and formation of senile plaques (Rogers et. Al, 1996).
Kang et al. reported in 1987 that amyloid plaques (AP) or develop from 
amyloid precursor protein (APP). APP is a ubiquitous Type 1 membrane 
glycoprotein and is generated throughout life in all mammalian cells (Haass, C. et 
al., 1992). APP is processed by P-secretase (BACE) and the presenilin- 
containing y-secretase complex (Haas, 2004). p-secretase cleaves APP to 
produce a soluble version of APP (P-APP) and a 99-residue COOH-terminal 
fragment that remains bound to the membrane. This 99-rsidue fragment is a 
substrate for y-secretase which performs the unusual cleavage in the middle of 
the transmembrane domain to produce a 4-kDa Ap (Yoo-Hun Suh and Frederic 
Checler, 2002). It is also worth noting that the APP gene is located on the 
chromosome 21, an extra copy of which characterizes Down Syndrome. Patients 
suffering from both of these diseases exhibit increase amounts of Ap proteins 
which leads to the formation of plaques (Mann and Esiri 1989). As suggested by 
Wisniewski et al. (1985) overprexpression of APP gene may accelerate the 
development of these neurodegenerative diseases although the cause is still not 
understood.
It is generally believed that the abnormal processing of APP leads to the 
aggregation and deposition of Ap and ultimately leads to the pathogenesis of AD.
This understanding is generally referred to as ‘amyloid cascade hypothesis’ and 
is supported by a large number of studies but is not entirely accepted (J. Hardy, 
2006).
The intracellular T-rich NFT’s are another feature of AD. Like AP plaques, 
NFT’s are formed by the aggregation of proteins that are on the inside of the 
neuron and gradually fill the intracellular space. The main component of these 
neurofibrillary tangles is microtubule-associated protein tau (C. Ballatore, 2007). 
Under normal conditions tau is bound to the microtubules comprising the 
neuronal skeleton and stabilizes their structure. In AD tau becomes detached 
from the microtubules and aggregates to form N FT’s. This process is also 
associated with phosphorylation of tau proteins which may be the onset of NFT 
formation. Thus, destabilized neuronal microtubules and NFT’s inclusions 
seriously impair neuronal function even before cell death. Tau aggregates as 
paired helical filaments (PHF) to form the NFT’s and in addition to that it is also 
found around senile plaques (Duyckaerts C, Dickson DW., 2003). There are 
several kinases that are involved in tau phosphorylation and formation of PHF’s 
in AD, such as stress activated c-Jun N-terminal kinase (SAPK/JNK) and p38 
kinase (p38), cyclin-dependent kinase-5 (CDK-5), glycogen synthase kinase-3p 
(GSK-3P) ( Lovestone, Reynolds, 1997). Moreover, there two to three phosphate 
groups per tau molecule in normal adult brain vs. hyperphosphorylation, which 
results in 7-8 mol phosphates in AD (Ksiezak-Reding et al., 1992; Kopke et al.,
1993).
Inflammatory responses may also be associated with AD onset. 
Documented occurrences of inflammatory processes in traumatic injuries to the 
CNS and in chronic diseases such as AD, suggest that inflammatory cytokines 
may be involved in neurodegenerative process (Schultzberg et al., 2007). 
Cytokines are small, multifunctional proteins that respond to injuries and infection 
and are produced by the glial cells when an inflammatory response is initiated. 
Some of the pro-inflammatory cytokines are interleukin-1 (IL-1), IL-6 and tumour 
necrosis factor-a (TNF-a) and are involved in the initiation of the inflammatory 
process. There are reciprocal interactions between proinflammatory cytokines 
such as IL-1 (3 and IL-6, and APP/(3-amyloid (A(3) peptide (Buxbaum JD,1992 and 
Del Bo R, 1995). Cytokines stimulate the synthesis and metabolism of APP and 
A(3 peptide induces the production and secretion of cytokines (Del Bo R, 1995). 
Depending on the A(3 peptide species and their aggregated forms the secretion 
of cytokines from rat neonatal microglia proceeds via different mechanisms. For 
instance, freshly dissolved A(3 peptides are more successful in initiating cytokine 
release than other larger forms (Lindberg C., 2005). Increasing release of 
proinflammatory cytokines regulates the processing and expression of APP  
which further leads to deposition of more A(3 fragments (Goldgaber D., 1989). 
Microglial cells eventually become unsuccessful in removing these plaques and 
lyse, releasing the collected fragments (Nagele et al., 2004). This recursive 
system continues leading to the expression of AD.
Mitogen-Activated Protein Kinases 
Mitogen-Activated Protein (MAP) kinases are serine/threonine-specific 
protein kinases that respond to extracellular stimuli and regulate various cellular 
activities. In mammalian cells the MAPK family consists of three main kinase 
subfamilies, the c-Jun-N-terminal kinases (JNKs), the p38 kinases, and the 
extracellular signal-regulated kinases (ERKs). The MAPK’s phosphorylate on 
specific serine and threonine residues of their target proteins. In addition, they 
propagate and amplify external stimuli coming from the membrane, going to the 
cytoplasm and finally reaching the nucleus by phosphorylating and 
dephosphorylating with the help of phosphatases. The c-Jun-N-terminal kinases 
regulate gene transcription and are able to influence degenerative processes that 
depend on de novo protein synthesis. The ERK subfamily is composed of ERK1 
and ERK2 and they are primarily involved in cell division, differentiation and 
proliferation. The p38 MAP kinases are encoded by four different genes 
(p38a,p,y,5). They get activated in times of stress by inflammatory cytokines. 
MAPK’s are ubiquitously expressed and are present in nervous tissue. Growing 
research suggests that p38 may be involved in neurodegenerative diseases such 
as AD by contributing to neuronal death (Bendotti, C, 2006). P38 is activated by 
double phosphorylation of Thr 180 and Tyr 182 in a Thr-Gly-Tyr motif near the 
active site in response to inflammatory stimuli such as TNF and IL-1 (3 (Ono, K. 
and Han, J., 2000). Interestingly, a substrate for p38 MAPK is tau protein. Once 
phosphorylated, tau can accumulate to form NFT which is one of the hallmarks of 
AD (Reynolds et al., 1997). P38 contributes to the neurotoxicity of A(3.
Cytokines -  Interleukin Family
Cytokines are low-molecular weight signaling proteins that are involved in 
many cell processes such as differentiation, proliferation and cell death. 
Cytokines can be divided according to their function. Some can be classified as 
growth factors, pro- or anti-inflammatory molecules or just aiding in the 
progression of immune response to an antigen. Cytokines are signaling 
molecules such as the interleukin family (IL), tumor necrosis factor (TNF) and 
many other growth factors. Cytokines can be classified in different families based 
on structure and activity. The TNF family includes more than 20 different 
members, encoded by different genes but with overlapping functions. The IL 
family includes 33 members, identified by a number 1-33. Some of the members 
of IL-1 subfamily include cytokines IL-1|3 and IL-1 a which function as pro- 
inflammatory molecules (Dinarello, C.A., 2007). The IL-6 family includes 
members such as IL-6, leukemia inhibitory factor (LIF), and IL-11. The IL-10 
family includes cytokines IL-10, IL-4 and IL-22 which are involved in inhibiting the 
immune response (Dinarello, C.A. ,2007).
The IL-1 family of cytokines consists of three members: IL-1 a, IL-1 (3 and 
their negative regulator (IL -Ira ). All three are encoded by a different gene but are 
similar on a structural level. IL-1 a and (3 are agonist molecules because they 
induce cellular responses. IL -Ira , however, binds to the same receptor but 
inhibits the signaling of IL-1 and is therefore considered an antagonist (Dinarello 
C A. 1994). IL-1 a and |3 have similarities both in gene sequences and 
structurally, being mainly composed of 12 to 14 folds of (3-pleated sheets (Murzin
A G, Lesk A M, Chothia C., 1992). In addition, the crystallographic structure of 
these cytokines reveals an Arg residue at the same position that is necessary for 
their biological function (Nanduri V  B. et al., 1991). Inflammatory and stress 
processes stimulate the transcription of IL-1 a and (3. In fact, Nawroth P. et al. 
(1986) reported that TN F-a can stimulate the production of IL-1 in endothelial 
cells. In addition, IL-1 or TN F-a  were also found to induce release of IL-13 in vivo 
(Dinarello G A., 1989). The IL -Ira  antagonist is primarily secreted in the 
extracellular environment and is composed of 3-pleated sheets, similar to IL-1a 
and 3 (Vigers G P. et al. 1994). Interestingly, IL -Ira  has only one binding site for 
its receptor, similar to IL-13, which was confirmed in a directed mutagenesis 
study by Evans et al. in 1995. This fact also explains the interruption of signal 
transmission in IL-I ra receptor antagonist.
Tumor necrosis factor-alpha (TNF-a) is a wide spread cytokine with 
various functions, such as promoting growth and inhibition, angiogenesis, 
inflammation and cytotoxicity. Many cells have been reported to produce and 
secrete TN F-a in response to infection or tumor growth. Immune cells are 
primarily involved in the release of this cytokine (Aggarwal B B, Natarajan K., 
1996). TN F-a is initially synthesized as a 26 kDa membrane-bound protein which 
later is cleaved to a mature 17 kDa form while its prosequence part remains 
associated with the membrane (Jue D M., 1990). Being one of the main pro- 
inflammatory cytokines, TN F-a plays a central role in initiating and regulating 
inflammatory processes. Bacterial lipopolysaccharide (LPS), injury, and viruses 
can stimulate the expression of TNF (Vassalli P., 1992). Notably, TNF along with
interferon gamma (IFN-y), potently stimulates other pro-inflammatory cytokines 
such as IL-1 and IL-6 which in turn activate T and B cells and stimulate lepatic 
acute phase protein synthesis. Interestingly, TNF is observed to be elevated in 
the serum, CSF and cerebral cortex in AD patients (H. Fillit, W .H . Ding, L. Buee 
et al., 1991). In 2001 Lucia et al. demonstrated that Ap induces production of 
TNF in rat microglia. In addition, TNF as well as IL -ip  were also found to exert 
both neurotrophic or neurotoxic effects, depending on their concentration and site 
of synthesis (Rothwell NJ, Hopkins SJ., 1995). This shows that TNF directly 
contributes to AD through subsequent neuroinflammation.
Interleukin-6 is another pleiotropic cytokine that is involved in inflammation 
processes in CNS. It is produced following viral or pathogen invasion as well as 
during inflammation (Van Snick J., 1990). The major species isolated from 
human T-cell line was reported to be an unglycosylated peptide with molecular 
mass between 19 to 21 kD (Hirano et al., 1985). Moreover, Santham et al. (1989) 
reported that secreted IL-6 is glycosylated and its molecular mass ranges from 
23 to 30 kD. Previous studies show that IL-6 acts through gp130 receptor and 
affects the functioning of B and T cells, neuronal cells and many others 
(Kishimoto T, Akira S, Narazaki M, Taga T., 1995). It is interesting to note that IL- 
6 has anti-inflammatory functions as well as a pro-inflammatory role. It induces 
the production of IL-Ira , which is a receptor antagonist of IL-1 and also 
decreases production of TNF (Tilg H, Dinarello CA, M ierJW ., 1997). By 
decreasing the amount of pro-inflammatory cytokines such as IL-1 and TNF, IL-6 
actually shows an anti-inflammatory role. However, it is found in high
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concentrations in tissues under stress and is able to take part in inflammatory 
processes. In addition, astrocytes and microglial cells in the CNS secrete IL-6 in 
times of infection or increased concentrations of other inflammatory cytokines. 
Moreover, it has been shown that IL-1P was able to activate the N FkB 
transcription factor and thus stimulate IL-6 promoter transcriptional activity 
(Zetterstrôm M. et al., 1998).
Signal Transduction Pathway of Interleukin - ip  
The IL-1 family consists of at least three proteins -  the agonist IL-1 a and P 
and the receptor antagonist IL -Ira . IL-1 a and P are synthesized precursor 
proteins. While IL-1 a is active in its precursor form, IL -ip  needs further cleavage 
by its converting enzyme (ICE; caspase-1), (Howard A D. et al., 1991). IL -Ira  
exists in three forms -  one secreted and known to block IL-1 activity, and two 
additional intracellular forms which are all encoded by the same gene (Muzio M. 
et al., 1995). There are two membrane bound receptors -  type I (IL-1RI) and type 
II (IL-1RII). The signal is initiated upon binding of IL -ip  to the type I receptor. The 
IL -IR II is believed to be a non signaling receptor, serving as a decoy and trap for 
IL-1 p. There is also an accessory protein involved in IL-1 signaling. The IL- 
IR A cP accessory protein, exhibits structural similarities to IL-1R subtypes but is 
unable to bind IL-1 alone. Instead, it forms a complex with IL-1RI and with any of 
the IL-1 agonists (Greenfeder S A. et al., 1995). IL-1 binds to its receptor and its 
accessory protein and this trimeric complex induces binding of myeloid- 
differentiation primary binding protein to the formed complex. This allows the
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recruitment of IRAK-4 and IRAK-1. Phosphorylation of IRAK-1 results in the 
binding of TRAP (TNF receptor associated factor)-6 to the initial complex. This 
on the other hand, allows the dissociation of a part of the complex (TRAF- 
6/phopho-IRAK-1) which binds to another membrane bound protein complex 
TAK-1. The phosphorylatioon of TAK-1 results in the degradation of IRAK-1, 
releasing the TRAF-6-TAK-1 from the protein complex associated with the 
plasma membrane (Akira, 2003). The fully activated TAK-1 protein activates 
various signaling molecules that activate many genes through transcription 
factors such as N F-kB. Interestingly, TAK-1 is also able to induce IL-1(3 mediated 
activation of MARK signaling.
Nuclear Factor -  kB 
Transcription nuclear factor - kB (NF-kB) belongs to the Rel family of 
proteins. It is a dimeric protein with each chain containing an N-terminal 300 
amino acids conserved region called the rel homology domain (RHD). This 
region is responsible for DMA binding and interaction with the N F-kB inhibitors, 
IkB (Ghosh, 1998). In the cytoplasm, NF-kB is associated with its inhibitors IkB 
preventing its migration to the nucleus for activated gene transcription. IkB is a 
large family of inhibitors which include IkB-o , (3, e and y. The best studied and 
characterized inhibitor is IkB-o , primarily due ti its initial discovery (Davis N., 
1991). In order to be activated, IkB-o needs to be phospshorylated on its N- 
terminal domain in response to chemical signals. IkB-(3 is less studied because it 
was characterized after IkB-o . However, they both bind the same Rel subunits
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but respond differently to chemical signals. The difference in activity may be due 
to strength or duration of signal. (Thompson J, 1995). Activated NF-kB promotes 
the transcription of IkB-o for feedback supression. On the other hand, NF-kB, 
once released from its inhibitor, does not promote transcription of IkB-|3. 
Interestingly, one can correlate this permanent activation of NF-kB to 
inflammatory processes in AD which further exacerbate neurodegeneration.
According to Spiecker et al., (2000), Ik B -e , which is much less studied 
than the previously discussed inhibitors, and its functional relationship with NF- 
kB is not well understood. Finally, previous research suggests that kB -y inhibits 
NF-kB by preventing it from binding to DNA by associating with different DNA 
binding residues (Bell et al., 1996).
NF-kB is initially associated with its inhibitor IkB which in times of 
inflammation is phosphorylated by IkB kinase (IKK), a type of transferase which 
usually transfers a phosphate group. The cell marks the phosphorylated 
molecule for further degradation in the proteosome by ubiquitination. The other 
product of the action of IKK is the released NF-kB which can translocate to the 
nucleus and initiate transcription of various genes. These genes can encode 
other pro-inflammatory cytokines such as IL-1, TNF and IL-6, which can further 
stimulate the inflammatory process. Thus, the activation of NF-kB can be 
assessed indirectly by measuring the degradation of its inhibitors.
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Y-Aminobutyric acid and catecholamines 
y-Aminobutyric acid (GABA) is one of the most important 
neurotransmitters in the CNS because it mediates membrane hyperpolarization 
and depolarization. It synthesis is accomplished by decarboxylation of glutamate 
by glutamic acid decarboxylase (GAD). GABA is then further modified and 
metabolized by the citric acid cycle. There are two classes of GABA receptors 
which are divided according to their function: the ionotropic receptor GABAa and 
the metabotropic receptor, GABAb. GABAa receptors are chloride ion channels 
which open following GABA binding. GABAa receptors are primarily composed 
of five different subunits each belonging to a different subclass (Sarto-Jackson I., 
2008). The GABAb receptor is a metabotropic G protein coupled receptor which 
initiates slow inhibitory responses. Activation of GABAb receptors increases 
potassium conductivity and decreases calcium currents which may be 
responsible for the amelioration of neurotransmission (Kerr and Ong 2001). 
Previous studies suggest that GABA can inhibit IL-1p mediated IL-6 release 
(Spangelo et al., 2004).
Other compounds that increase the intracellular level of cAMP also induce 
IL-6 release. Catecholamines are derived from tyrosine and contain catechol and 
amine groups. The catecholamines include epinephrine (adrenaline), 
norepinephrine (noradrenaline) and dopamine. Catecholamines are hormones 
secreted form the adrenal gland in response to not prolonged stress. Their mode 
of action is through elevating cAMP intracellular levels. Other drugs which 
elevate cAMP include cholera toxin and BuacAMP. In fact, previous results
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showed that BuacAMP increases IL-6 mRNA accumulation in and IL-6 release 
from anterior pituitary cells (Spangelo et al., 1990). Interestingly, catecholamines 
are also able to stimulate the synergistic release of IL-6 in the presence of 
another cytokine, IL -ip  (Zumwalt et al., 1999). This is important in disease 
processes in the CNS where the level of cytokine production is elevated in 
response to stress. Since AD is characterized by neurofibrillary tangles and 
senile plaques, production of IL-1 and IL-6 may further exacerbate the 
pathogenesis of this condition. Increasing levels of IL -ip  may also increase 
levels of catecholamines which can further increase production of IL-6 and 
stimulate neuronal degradation.
Interleukin-10: An Anti-Inflammatory Cytokine 
Astrocytes and microglial cells are activated in response to cellular injury 
and brain trauma. Glia function in regulating the inflammatory reaction and 
neuronal tissue repair in the CNS (Ridet et al., 1997). Astrocytes secrete 
cytokines and they also express membrane cytokine receptors suggesting that 
they can be targets of pro-inflammatory cytokines like IL -ip , TNF-a, or IL-6 (Ban 
et al., 1993). IL-1 is well known to cause cell death of neurons and to induce 
astrogliosis by the production of stress molecules such as nitric oxide (NO), 
arachidonic acid derivatives, or cytokines (Lee et al., 1995). To counter this 
process, the organism uses different tactics including the expression of IL -Ira  
type II receptor ‘decoy’ and production of the anti-inflammatory cytokines IL-10 
and IL-4. Moore et al., 1993 showed that IL-10 inhibits the production of the pro-
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inflammatory cytokines IL-1P, TN F-a and IL-6. Interleukin-10 was first described 
by Fiorentino et al. in 1989 as a cytokine synthesis inhibitory factor (CSIF). First 
described as an inhibitor of cytokine synthesis, it was classified as a Th-1- 
immunosupressive cytokine similar to interferon gamma and tumour necrosis 
factor-alpha. CSIF was later cloned from human cDNA (Vieira et al., 1991) and 
renamed IL-10. The human IL-10 gene encodes a protein of 178 amino acids 
which is cleaved to produce a mature sequence of about 18kDa, containing four 
cysteine residues (Windsor et al., 1993). It is noteworthy to mention that IL-4 is 
another anti-inflammatory cytokine with similarities to IL-10. For instance, IL-10 is 
synthesized in the normal brain (Wong et al., 1996) and in times of inflammation 
and brain injury both cytokines are expressed (Woodroofe et al., 1993). Glial 
cells were proposed to be major sources of IL-10 as well as IL-4 (Mizuno et al.,
1994). Pousset et al., 1999 proposed that IL-4 and IL-10 might be active at 
different stages of the inflammatory response. Previous research investigated the 
effects of these anti-inflammatory cytokines on IL -ip  induced IL-6 production by 
mouse primary astrocytes and reported that IL-4 and IL-10 differentially regulate 
IL-6 levels in activated astrocytes. They further suggested that IL-10 has anti­
inflammatory properties while IL-4 represents stimulating effects depending on 
the cell type and cytokine environment (Pousset et al., 2000).
IL-10 activates the Jak/stat signaling pathway. It is suggested that IL-10 
interferes with the Jak family tyrosine kinases by inducing tyrosine 
phosphorylation and activating transcription of latent transcription factors stat3 
and Statl (Finbloom DS, Winestock KD., 1995). In addition, it was also reported
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that IL-10 inhibits NF-kB activation in response to stimuli. This accomplished by 
two plausible mechanisms. The first is by inhibiting the activation of IkB kinase, 
and the second, by inhibiting NF-kB DNA binding activity (Schottelius et al., 
1999). Furthermore, Pousset et al., 2000 reported that intracellular signaling 
pathways such as NFkB and Akt may be connected and downregulated by IL-4 
and IL-10. Previous results also suggested that these anti-inflammatory cytokines 
may block the inflammatory effects of IL -ip  through these pathways in 
astrocytes.
The anti-inflammatory properties of interleukin-10 need to be further 
investigated in light of its known functions of macrophage activation and T cell 
cytokine synthesis (Moore et al., 1993). Also, by further investigation of anti­
inflammatory cytokines and chemokines, inflammatory processes in 
neurodegenerative diseases such as AD can be better understood.
Hypothesis Statement
Although IL-10 has been studied as an anti-inflammatory cytokine, its 
effects on astrocytes and in particular C6 glioma cell line, need to be further 
investigated. As reported previously, IL-10 interferes with N F kB signaling 
pathway (Pousset et al., 2000). Since N FkB signaling pathway as well as p38 
can also be activated by IL -ip  and TN F-a to induce the release of IL-6, we 
hypothesize that : [1] IL-10 inhibits the synergistic induction of IL-6 mediated by 
IL -ip  and TNF-a; and [2] IL-10 may also interfere with IL-6 transcription induced 
by TN F-a and IL -ip .
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CHAPTER 2
MATERIALS AND M ETHODS  
Chemicals, Reagents and Equipment 
y-Aminobutyric acid (GABA), glycine, sodium chloride (NaCI), potassium 
chloride, 4-(2-hydroxyethyl)-monosodium salt (HEPES), sodium dodecyl sulphate 
(SDS), tris-(hydroxymethyl)amino-methane (Tris), tris-(hydroxymethyl)amino- 
methane hydrochloride, Tween-20, dimethyl sulfoxide (DMSG), 2- 
mercaptoethanol (P-ME), and bromophenol blue were obtained from Sigma- 
Aldrich (St. Louis, MO) and were of the highest grade possible. High molecular 
weight poly-D-lysine (PDL) hydrobromide was obtained from BD Biosciences 
(Bedford, MA). The prestained protein ladder was obtained from Bio-Rad 
(Hercules, CA). Roswell Park Memorial institute (RPM I)-1640, PSN antibiotic 
mix, trypsin-ethylenediaminetetraacetic acid (EDTA), heat-inactivated fetal 
bovine serum (FBS), phosphate buffer saline (PBS pH 7.2), RNeasy MINi Kit, 
quantiTec Reverse Transcription Kit and QIashredder were obtained from 
QIAGEN, USA. Trypan blue was obtained from Invitrogen (Carlsbad, CA). 
Methanol was obtained from EMD Chemicals (Gibbstown, NJ). Bovine serum 
albumin (BSA) was obtained from Gemini Bioproducts (Woodland, CA). 
Recombinant rat IL -ip , TNF-a, IL-10, IL-4 and anti rat IL-6 antibodies were
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obtained from PeproTech Inc. (Rocky Hill, NJ). Rabbit anti-rat IkB-q , IkB-P, 
phosphorylated p38 (T180/Y182), total p38, rabbit anti-rat IL-6 antibody, p-Actin 
and the biotinylated protein ladder was obtained from Cell Signaling (Danvers, 
MA). Goat anti-rabbit and goat anti-mouse horseradish peroxidase (HRP) 
conjugated secondary antibodies were obtained from KPL (Gaithersdurg, MD). 
The rat C6 Glioma cell lines were obtained from the American Tissue Type 
culture Collection (Rockville, MD). Rat IL-6 sandwich enzyme-linked 
immunosorbent assay (ELISA) kits, M -PER®, precasted 12% SDS- 
polyacrylamide gel electrophoresis (PAGE) gels, protease and phosphatase 
inhibitor cocktails, and the microBCA® [rotein assay kit were all obrained from 
Pierce Biotechnology (Rockford, IL). Hoefer SE 260 minivertical gel 
electrophoresis unit, EPS 2A200 Power supply, Hoefer TE 22 tank transfer unit, 
MultiTemp III thermostatic circulator. Enhanced Chemilminescence (ECL)-Plus®  
detection reagent was obtained from Amersham (Piscataway, NJ). Schleicher & 
Schuell Optitran® brand supported 0.45 um nitrocellulose membranes were 
obtained from ISC Bioexpress (Kaysville, LIT). Rabbit anti-rat IL-6 antibody was 
purchased from Cell Sciences (Canton, MA). All small molecule inhibitors 
dissolved in sterile solvent, aliquoted and stored at -20°C  until use. The final 
concentrations of DM SO  never exceeded 0.1%  of the final solution.
C6 Glioma Cell Culture 
Rat C6 glioma cells were maintained in continuous culture in a humidified 
atmosphere containing 95%  air and 5% CO 2 in complete medium (RPM I-1640/
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phenol red, medium containing 10% heat-inactivated FBS, 25mM HEPES pH 
7.4, and PSN antibiotic mix). Cells were grown either in 25 cm^ or 75 cm^ area 
flasks. After 3-4 days in culture, cells were removed from the tissue culture flasks 
v\/ith 2 mL (for the 25 cm^ area flask) or 6 mL (for 75 cm^ area flask) of 0.25%  
trypsin/ 0.05%  EDTA in Hanks-buffered salt solution. Trypsin was inactivated 
upon the addition of 8-24 ml of complete medium, cells were centrifuged, 
pelleted, supernatant removed, and the pelleted cells resuspended in complete 
medium. Cell suspension densities and cellular viability were determined via 
trypan blue exclusion. The cells were then placed (passed) back into continuous 
culture (1.25x10® cells/25 cm^-area flask, BD Falcon) or were seeded into tissue 
culture plastic-ware at the plating densities noted for experiments. In all 
experiments presented, C6 glioma cells were used between passages 5-35.
Cytokine Quantification via ELISA  
Rat C6 cells were plated (0.125x10®/well) on a 96-well plate using Poly-D-Lysine 
(PDL) in complete medium and allowed to incubate 24 h to ensure attachment. 
For the experiment, cells were washed twice with 2mll serum-free RPMI 1640 
and incubated serum or serum-free RPM I-1640 in the absence or presence of 
agents for the times and doses indicated for the experiments. IL-6 release was 
then assayed via rat IL-6 ELISA (Pierce Biotechnology) according to the 
manufacturers’ instructions.
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Colletion of Cellular Protein Lysates 
Rat C6 glioma cells were plated (3.0x10®/dish) on PDL-coated 35x10mm dishes 
in complete medium and allowed 24 h to attach. Following the attachment period, 
the cells were washed twice with 2ml serum-free RPM I-1640 and incubated in 
serum or serum-free RPM I-1640 in the absence or presence of stimulating 
agents for the times and concentrations. After treatments cells were washed 
twice in 2ml ice cold PBS and scraped in 200pL of M -P ER ®  (Pierce), containing 
both phosphatase and protease inhibitors (each from Pierce). Protein- containing 
solutions were kept on ice and vortexed in 10 min intervals for a total time of 30 
min on ice. Lysates were then centrifuged at 14,000 x g for 10 min at 4°C, and 
175pL of the supernatant was recovered. Protein concentrations were 
determined with Micro-BCA protein assay kit (Pierce) using BSA as a standard. 
Protein lysates were diluted by 20%  using a 2X SDS-PAG E loading buffer (10%  
w/v SDS, 2% v/v glycerol, 0.1%  w/v bromophenol blue, 0.5M  Tris pH 6.8, and 5%  
v/v P-ME), and boiled for 2 min. Protein lysates were subsequently separated by 
SDS-PAGE Western blot analysis or at -80°C for future analysis.
RNA Extraction and Semi-Quantitative RT-PCR Analysis 
Rat 0 6  glioma cells were plated (3.0 X 10®/dish) on PDL-coated 35 X 10mm 
dishes in complete medium, and allowed 24 h to attach. Following the 
attachment period, the cells were washed twice with 2 ml serum-free RPMI-1640  
and incubated in 10% FBS RPM I-1640 in the presence or absence of stimulating 
agents for the times and doses indicated for the experiments. After treatments
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cells were washed twice in 2ml ice cold PBS. Total RNA was then extracted 
using QIAGEN RNeasy MINI Kit purification system.
To detect the presence of mRNA encoding IL-6 and P-Actin, semi- 
quantitative RT-PCR analysis were performed as described by Elsawa et al., 
2004 and Bost et al., 1995. One pg of the total RNA was reverse transcribed 
using QuantiTec Reverse Transcription Kit (QIAGEN) and apportion of the total 
cDNA was amplified using 94°C dénaturation, 55°C annealing and 72°C  
extension temperatures, for 30 cycles with the first four cycles having extended 
times. Positive and negative strand primers used for the amplification of each 
mRNA species were obtained from QIAGEN, USA. Specific sequences were not 
supplied because of company propriety rules. Amplified products were 
electrophoresed on 0.5pg/ml ethidium bromide stained gels and visualized under 
UV illumination. Analysis of cDNA samples were corrected for expression of P- 
Actin.
SDS-PAGE Western Blot Analysis 
Protein lysates were separated on a SDS-PAGE gel. Poly-acrylamide gles were 
purchased precasted (Pierce). The gels were subsequently transferred to a 
Hoffer (0.1 M HEPES, 0.1 M Tris, 0.1%  w/v SDS) running buffer. Equal amounts 
of protein were loaded into each lane of the precast gel. Biotinylated and 
prestained protein ladders were also loaded onto the stacking gel to determine 
the molecular weight mobility and transfer efficiency, respectively. The proteins 
were electrophoretically separated at 4°C, using a constant voltage of 100V.
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Following electrophoresis, the proteins were transferred (Hoefer TE22 Mighty 
Small TransPhor Tank, Amersham) to 0.45 pm nitrocellulose membranes at 4°C, 
using constant amperage of 360 mA for 90 min in Western Transfer buffer (25 
mM Tris, 192 mM Glycine, and 20% v/v methanol, note: pH was not adjusted). 
Following the transfer period, protein-containing membranes were washed once 
for 5 min in tris-buffered saline containing tween (TBST: 50mM Tris pH 7.4, 150 
mM NaCI, and 0.1 % v/v Tween-20) for 5 minutes. After the washing period the 
membranes were blocked with TBST containing 5% nonfat milk (Nestle 
Carnation) for 1 hour, then washed three times in 5 min intervals in TBST. The 
membrane was incubated 12 h with primary antibodies at 4°C. After the antibody 
incubation period, the antibody solution was removed and the membranes 
washed in TBST three times for 5 min intervals. Membranes were then incubated 
with a secondary antibody conjugated to a horseradish peroxidase (HRP) and 
anti-biotin. Both secondary and anti-biotin antibodies were diluted using the 
manufacturers’ recommendation, of 1:5000 and 1:1000, respectively. All 
antibodies were diluted in TBST containing 5% BSA. The incubation period for 
secondary antibody and anti-biotin w asi h and afterwards both were removed 
and washed in TBST three times for 5 minute intervals. Proteins were visualized 




Statistical analyses consisted of analysis of variance (ANOVA), with 
significance confirmed using the Bonferroni test for multiple comparisons 
(GraphPad Instat, version 3.0). A P-value of < 0.05 was considered significant. 
Where appropriate, data expressed as the mean ± SEM of groups consisting of 





Other inhibitory modulators and their effects on IL-13 signaling 
W e investigated the effects of various signaling molecules, both inhibitors and 
enhancers of two signaling pathways: NF-kB and p38 MARK. The effects of 
serotonin (5-HT) and lipoic acid (LA) on IL-13 mediated phosphorylation of p38 
were investigated in a Western format. As suggested in literature, these inhibitory 
molecules are potent anti-inflammatory mediators. IL-13 successfully 
phosphorylates the total p38, but 5-HT was unable to reverse the effects of this 
cytokine (Figure 2). Moreover, different concentrations of 5 -H T were not able to 
reduce the p38 phosphrylation induced by IL-13 (Figure 3).
Modulators affecting cAMP 
Bu2cAMP increases cAMP and therefore the phosphorylation of p38 however, no 
synergistic effect was observed with IL-13 and Bu2cAMP co-treatments (Figure 
2).The effects of cholera toxin (CT), norepinephrine (NE) and isoprotrenolol (IPT) 
were investigated and compared to that of 5-HT by Western blot format. CT and 
NE were postulated to synergise IL-13 mediated phosphorylation of p38. NE acts 
through the 3- adrenergic receptor to increase intracellular levels of cAMP but
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showed no synergistic induction in p38 phosphorylation when applied together 
with IL-1 p. However, IPT showed decrease in p38 phosphorylation (Figure 4). 
W e further investigated the effects of IPT on IL -ip  signaling. Our results showed 
no further proof of IPT decreasing IL -ip  mediated phosphorylation of p38 
(Figure 5).
Effects of lipoic acid on IL -ip  signaling 
W e investigated the effects of LA and its potential in inhibiting the signaling of IL- 
ip  and TNF-a. W e observed that both IL -ip  and TN F-a induced p38 
phosphorylation and IkB-o degradation with no effect on total p38 and kB -p. 
Lipoic acid was not able to reverse the activation of either pathway mediated by 
IL-1 p or TN F-a (Figure 6, 7)..
Effects of serum vs. serum free medium on IL-6 ELISA assay 
W e next investigated the effects of serum (10% FBS, RPMI - 1640) versus serum 
free (RPMI - 1640) in ELISA format. Both methods showed good standard curves 
with high R values (results not shown). A robust synergistic release of 
extracellular IL-6 due to IL -ip  and TN F-a was observed in both experiments 
(Figure 8 -  Panel [A] and [B]). Both GABA and IL-10 were able to suppress the 
synergistic induction of IL-6, suggesting that they may have the same mode of 
anti-inflammatory action. In addition, serum conditions showed larger fold 
suppression of IL-6 induction than serum free (RPM I -  1640) (Figure 8,).
26
Interestingly, serum free samples had more IL-6 in pg/well than 10% FBS RPMI - 
1640 alone.
Effects of concentration of IL-10 and GABA on extracellular IL-6 release 
Having determined that serum containing medium allows for better fold induction 
suppression of IL-6, we characterized the dose response effects of IL-10 and 
GABA on IL-6 suppression. In serum containing medium, we showed the highest 
concentrations of GABA and IL-10, 1 mM and 100 ng/ml, respectively, were able 
to best suppress the synergistic induction of IL-6 due to IL -ip  and TNF-a. W e  
also showed that even lower concentrations of GABA (0.2 mM) and IL-10 (10 
ng/ml) induced some suppression of release of IL-6 (Figure 9).
Extended dose response of IL-10 on extracellular IL-6 release 
Once we determined that the IL-10 reverses the synergistic induction of IL-6 due 
to IL -ip  and TN F-a, we investigated its effects in an extended dose response. 
Groups were treated with 1, 5, 10, 25, 50 and 100ng/ml of IL-10. Highest 
concentration of IL-10 (100ng/ml) most efficiently suppressed the IL-6 release. 
Furthermore, concentrations as low as 1 and 5 ng/ml IL-10 reduced the 
synergistic release of IL-6 (Figure 10).
Effects of IL-4 compared to IL-10 and GABA in ability to suppress extracellular
IL-6 release
W e decided to test the test the effects of IL-4, a similar cytokine to IL-10, 
believed to have the same effects on IL-6 suppression. IL-4 was able to suppress
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IL -ip  and TN F-a synergism in inducing IL-6 release almost the same fold as 
GABA and IL-10. further, SB203580, an inhibitor of p38 activity completely wiped 
out the signal of IL-6 release, suggesting involvement of p38 MAP kinase in this 
pathway (Figure 11).
Effects of serum vs. serum free in Western format 
The effects of serum vs. serum free medium in the ELISA assays suggested that 
serum medium was to be our working medium. W e had to standardize this 
procedure for our Western format, so we investigated the same effects in a 
Western blot. Both IL -ip  and TN F-a were able to induce the phosphorylation of 
total p38 and the degradation of k B -a  (inhibitor of NF-kB), but not kB -p. W e also 
showed synergy of the two cytokines in their ability to induce those two signaling 
pathways. IL-10 (100 ng/ml) was unable to reverse the effects from IL -ip  and 
TNF-a. Also, we once again showed that serum conditions (10%  FBS in RPMI - 
1640) allowed greater induction of p38 phosphorylation, k B -a  degradation, and 
cellular accumulation of IL-6 (Figure 12). Furthermore, we performed separate 
experiments involving serum vs. serum free conditions and compared the effects 
of GABA and IL-10 on IL-1 P and TN F-a signaling (Figures 13,14).
Effects of different concentration of IL -ip  on p38 phosphorylation 
After having determined that serum rich conditions are optimal for our 
experiments, we investigated the role of IL-10 on IL -ip  and TN F-a signaling. W e  
further explored the idea that IL-10 may affect IL -ip  signaling at low
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concentrations for this pro-inflammatory cytokine. W e found that IL-13 was able 
to stimulate phosphorylation of p38 even at concentrations as low as 10 ng/ml. In 
addition, IL-10 did not inhibit the p38 activation due to low concentrations of IL- 
ip . Furthermore, IL-10 did not induce any activation of p38 when administered 
alone (Figure 15).
Effects of different concentrations TNF-a on p38 phosphorylation 
Since we determined that IL-10 had no effect on IL -ip  induced p38 activation, we 
decided to test another hypothesis that IL-10 may affect the TN F-a mediated 
phosphorylation of p38. W e found that TNF-a, like IL -ip  induces activation of p38 
even at low concentrations of 10 ng/ml. W e observed a dose response of TNF-a  
on p38 activation. IL-10 did not reverse the effects of TN F-a on p38 at any 
concentrations of the co-treatments (Figure 16).
Effects of different concentration of IL -ip  on IkB degradation 
W e further investigated the effects of IL-10 on IL -ip  mediated degradation of IkB- 
a in NF-kB signaling. As expected, IL-1 p was able to initiate degradation of kB -a, 
inhibitor of N F-kB, with no change in kB-p. However, IL-10 was not able to 
reverse kB -a  degradation even at lowest concentrations of IL -ip  of 10 ng/ml. 
Moreover, IL-10 alone had no effect on kB -a  degradation (F igure 17).
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Dose response effects of TN F-a on degradation of kB -a: role of IL-10 
W e also investigated the hypothesis that IL-10 may have a role on TN F-a  
mediated NF-kB signaling. TNF-a activated the degradation of the N F-kB 
inhibitor k B -a  at 10 ng/ml. W e also observed a dose response of TN F-a in NF­
kB signaling. Some decrease in the intensity of the bands was observed when 
co-treatments with IL-10 were administered. This suggested that IL-10 may have 
a modest effect on TN F-a mediated kB -a  degradation. IL-10 had no effect on 
degradation of kB -a , as shown in previous experiments and neither of these 
cytokines showed any change in kB-P, as expected (Figure 18).
Effects of IL-10 and IL-4 on IL -ip  and TN F-a mediated synergistic p38 activation
and kB -a  degradation 
W e previously showed in an ELISA format that IL-10 and IL-4 inhibited the 
cytokine synergistic release of IL-6. W e decided to further investigate the 
hypothesis that these two anti-inflammatory cytokines may decrease intracellular 
levels of IL-6 by reversing p38 phosphorylation and k B -a  degradation induced by 
TNF-a and IL-1 p. As expected, both cytokines, TN F-a and IL -ip , induced p38 
phosphorylation and kB -a  degradation in a synergistic fashion. IL-10 and 11-4, 
however, did not have any effect on these two signaling pathways. There was no 
change in k B -a  or total p38, as shown before by any of the cytokines (Figure  
19). In addition, we also included the effects in JNK phosphorylation where IL-10 
was able to reduce the phosphorylation of JNK mediated by TN F-a and IL -ip .
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Time course of TN F-a and IL-1P synergism on IL-6 release 
W e decided to investigate the optimal time response for IL-6 induced by TNF-a  
and IL-1 p. Interestingly, both cytokines induced IL-6 intracellular levels at their 
optimal concentrations, 100 ng/ml and 50 ng/ml, respectively. Moreover, 
differences in time course were not observed for any of the treatment groups and 
IL-6 remained unchanged for 1 h to 6 h (Figure 20).
Effects of IL-10 and GABA on TN F-a and IL -ip  signaling 
W e investigated the effects of longer intervals of TN F-a and IL -ip  signaling (in, 4 
h and 6 h). Previously, we found that even at an extended time response both 
cytokines are able to stimulate the degradation of k B -a  and release of IL-6 
(results not shown). On the contrary, IL-10 and GABA, did not reverse the effects 
of inflammatory cytokines on NF-kB signaling or change intracellular IL-6. 
Moreover, levels of p-actin and kB -P  remained unchanged. In addition, levels of 
IL-6 stimulation remained the same at both 4 h and 6 h treatment groups (Figure 
21).
Effects of TN F-a and IL -ip  on short time treatment in accumulation of
intracellular IL-6
Previous results suggested that accumulation of intracellular IL-6 remained 
unchanged in treatments from 1 h to 6 h. W e first expanded the time response 
from 2, 4 to 24 hours (Figure 22). Surprisingly, IL-6 content remained the same 
throughout the time response. Total p38, kB -p  and P-actin remained also
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unchanged as expected. The phosphrylation of p38 however, showed stimulation 
by both TN F-a and IL -ip , and interestingly, was decreased by IL-10 at 2 and 4 h 
treatment. W e decided to constrict the time frame of measuring IL-6 at 15 min 
and 30 min. W e also included the effects of GABA, IL-4 and IL-10 on TN F-a and 
IL -ip  signaling (Figure 23). All anti-inflammatory modulators showed decrease in 
p38 phosphorylation after stimulation with TNF-a and IL -ip  at 30 min. No effect 
was observed at 15 minute treatments and no change was observed in IL-6 
content throughout. Total p38, kB -p  or p-actin were not altered as expected.
Synergistic transcriptional activation of IL-6 mediated by TN F-a and IL -ip .
Effects of IL-10 and GABA 
W e then proceeded to investigate the transcriptional activation of IL-6 mRNA. 
Interestingly, TN F-a and IL -ip  are able to synergistically stimulate the 
transcription of IL-6. GABA and IL-10, however, were not able to reverse this 
synergistic response. W e also tested SB203580 compound, known to interfere 
and inhibit p38 activity. In fact, SB203580 was able to completely suppress IL-6 
transcriptional activation mediated by TNF-a and IL -ip , suggesting its 
involvement in this signaling pathway (Figure 24).
Effects of IL-10 on JNK MAP kinase activation 
Since IL-10 did not interfere with p38 or NF-kB signaling, we decided to explore 
the possibility of its interference with JNK kinase, another MAP kinase. 
Surprisingly we found that IL-10 reversed the phosphorylation of JNK induced by
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TNF-a and IL-1p suggesting a plausible interference point of IL-10 in our 




Synergistic interaction between Interleukin-1 P and catecholamines 
After extensive literature review we decided to study the effects of 
catecholamines and other signaling molecules increasing intracellular level of 
cAMP on IL -ip  signaling pathway. J. Zumwalt et al., 1999 previously showed 
synergistic release of IL-6 mediated by IL -ip  and Bu2cAMP, cholera toxin, 
norepinephrine and isoprotenolol. Our lab previously showed that IL -ip  
stimulates p38 phosphorylation and kB -a  degradation which ultimately leads to 
release of IL-6 (data not shown). W e tested the synergistic effects of IL -ip  
together with BU2CAMP, cholera toxin, norepinephrine and isoprotenolol on p38 
phosphorylation (Figure 4, 5). Optimal treatment times for stimulation of p38 by 
IL -ip  was determined previously to be 15 min. Co-treatments with 
catecholamines were not able to increase activation of p38 in a synergistic 
manner. W e determined that optimal concentrations of Bu2cAMP (1 mM), CT  
(250 ng/ml), NE (100 pM) and IPT (10 pM) as suggested by literature, were not 
able to increase p38 phosphorylation. This suggests that their synergism in IL-6 
release may go through a different pathway other than p38 MAPK. Moreover, 
catecholamines did not stimulate p38 phosphorylation when administered alone.
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W e also investigated the effects of other inhibitors and modulators such as 
Serotonin (5-HT) on p38 activation mediated by IL-1 p. Previous research 
suggested that 5-HT was able to reverse IL-6 m RNA expression in MC-3 cells 
(C. Mahe et al., 2005). Our results concluded that 5-H T was not able to inhibit 
and reverse the phosphorylation of p38 induced by IL -ip  and therefore may not 
inhibit IL-6 gene transcription through this pathway (Figure 2, 3).
W e further investigated the effects of lipoic acid on IL -ip  stimulated p38 
and NF-kB pathways. W e expected that lipoic acid would be a potent inhibitor of 
IL -ip  mediated activation. However, our results showed that lipoic acid was not 
able to reverse the effects of IL-1 p stimulation (Figure 6, 7).
Interleukin-10 inhibition of the synergistic release 
of IL-6 by TN F-a and IL-1 p 
Our lab has previously established that TN F-a and IL -ip  combined induce a 
synergistic effect on IL-6 release (Roach et al., in press). Previous research also 
introduced the effects of GABA on the inhibition of IL-6 release induced by TNF-a  
and IL-1 p. W e investigated the effects of the anti-inflammatory cytokine, IL-10, on 
the synergistic release of IL-6 in ELISA format. Pousset et al. (2000) showed that 
infalmmatory cytokine IL -ip  can induce NF-kB activation in primary mouse 
astrocytes. Furthermore, they showed that anti-inflammatory cytokines IL-10 and 
IL-4 were able to block the IL -ip  induced N F-kB activation. W e further 
investigated this idea and studied the effects of IL-10 on IL -ip  and TNF-a  
mediated p38 phosphorylation, NF- kB activation and release of IL-6 in rat C6
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astrocytes. In order to further understand the fold induction of IL-6 release and its 
suppression, we explored the effects of serum containing medium (10% FBS, 
RPMI - 1640) vs. serum free medium (RPMI - 1640). Our results indicated that 
serum rich containing medium induced better fold suppression of synergistic 
induction of IL-6 by GABA and IL-10 (Figure 8). Synergistic extracellular IL-6 
release was best suppressed at optimal concentrations for GABA (1 mM) and IL- 
10 (100 ng/ml) in serum. W e also observed that serum free treatments induced 
larger release of IL-6 but we achieved greater fold suppression when treatments 
were made in serum rich medium. W e were also able to generate a dose 
response of GABA and IL-10 in ELISA format showing dose dependence of 
inhibitory modulators over inflammatory cytokines, IL -ip  and TN F-a (Figure 9). 
Lowest doses of GABA and IL-10, 0.2 mM and 10 ng/ml, respectively, just 
slightly suppressed IL -ip  and TN F-a synergism. However, highest doses of 
GABA (1 mM) and IL-10 (100 ng/ml) suppressed IL-6 induction by approximately 
50%. In addition, when GABA and IL-10 were administered alone, no change in 
IL-6 release was measured.
To determine the minimal and maximal effective doses of IL-10 in reducing IL- 
6 in ELISA, we performed treatments with six different doses ( 1 - 100ng/ml). Co­
treatments of IL -ip  and TN F-a together with IL-10 inhibited IL-6 release at 100 
ng/ml IL-10. Moreover, 1 ng/ml IL-10 of also slightly suppressed IL-6 release 
(Figure 10).
Further, we compared inhibition of IL-6 release by IL-10 and GABA to that of 
IL-4 and SB203580 in ELISA. As suggested by the literature, IL-4 has anti­
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inflammatory properties similar to IL-10 (F. Pousset et al., 2000). W e expected to 
observe IL-4 inhibition of IL-6 similar to that of IL-10. In fact, IL-4 suppressed IL- 
ip  and TN F-a synergistic induction of IL-6 similarly to IL-10 and GABA (Figure 
11). In addition, SB203580, a p38 inhibitor, completely reversed the effects of IL- 
ip  and TN F - 0  on IL-6 release. Our results show that each of these anti­
inflammatory cytokines and inhibitors in the CNS may have a similar mode of 
action. J. Roach, et al., (2008) suggested that GABA may inhibit IL-6 translation 
by blocking IL-6 transcript release form the nucleus or by inhibiting translation 
directly. With these results we can prove our first hypothesis that IL-10 inhibits 
synergistic induction of IL-6, due to TNF-a and IL -ip . From the data presented, 
we decided to investigate further the effects of IL-10 on p38 and NF-kB activation 
by Western.
Effects of Interleukin-10 inhibition on IL -ip  and TNF-a mediated induction of
IL-6
Since accelerated effect of p38 phosphorylation and NF-kB activation, 
induced by IL -ip  and TN F-a may be the cause for synergistic induction of IL-6 as 
shown in our ELISA data, we needed to investigate IL-10 activation of these two 
pathways. First, we had to determine our optimal working conditions in serum 
rich or serum free medium. Results indicated that synergistic activation of p38 
and NF-kB was better expressed in serum containing medium (Figure 12). W e  
showed that IL-10 did not consistently reverse p38 phosphorylation or IkB-o 
degradation induced by IL -ip  and TNF-a. W e observed the expected synergism
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of the two inflammatory cytokines as expected. However, IL-10 100 ng/ml and 15 
min co-treatments was unable to show any effect. In addition, we observed no 
change in total p38, IkB-3, 3-actin, as expected. Moreover, IL-10 did not reduce 
intracellular accumulation of IL-6. W e once again confirmed that treatment with 
100 ng/ml TN F-a and 50 ng/ml IL -ip  resulted in IL-6 transcription and synergistic 
induction of p38 and NF-kB. However, IL-10 did not interfere with p38 and IkB-o 
activation.
W e also demonstrated that GABA showed little or no difference in the IL -ip  or 
TNF-a stimulation of p38 and NF-kB in serum free or serum rich medium (Figure 
13, 14). The reason for this difference of GABA to IL-10 experiment in serum vs. 
serum free conditions may be due to the fact of different cell split number or other 
experimental conditions.
W e also illustrated dose dependence activation of p38 pathway by IL -ip . 
Lowest doses of IL -ip  at 10 ng/ml were just slightly able to induce 
phosphorylation. On the other hand, highest concentrations of 100 ng/ ml of IL -ip  
showed a great induction of p38. Moreover, IL-10 was not able to inhibit IL -ip  
activation of p38 at any dose of IL -ip . Maximal concentrations of IL-10 of 100 
ng/ml were used for co-treatments (Figure 15). W e investigated TN F-a  dose 
dependence on p38 activation and IL-10 effects. Results show that TNF-a  
stimulated p38 phosphorylation at 10 ng/ml as well as at 100 ng/ml. Once again, 
IL-10 did not reverse TN F-a effects on p38 phosphorylation (Figure 16). These 
results indicate that IL-10 has no effect on stimulated p38 pathway and therefore
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may not have an effect on intracellular accumulation of IL-6 message, which may 
be stimulated by acceleration of phosphorylation of p38.
The activation of NF-kB on IL-6 accumulation was also studied. Dose 
dependence of both IL -ip  and TN F-a was observed to activate IkB-o degradation 
with no change in kB -p. In either scenario, IL-10 did not reverse IL -ip  or TNF-a  
stimulated degradation of IkB-o (Figure 17 ,18 ).
Our ELISA data shown before suggested that IL-10 inhibits synergistic 
release of IL-6 mediated by IL I-P  and TNF-a. Therefore, we decided to 
investigate further this response by Western. NF-kB and p38 activation was 
stimulated synergistically by IL I-P  and TNF-a at maximal concentrations of 50 
ng/ml and 100 ng/ml, respectively. Both anti-inflammatory cytokines, IL-10 and 
IL-4 had no effect on IkB-o degradation or phosphorylation of p38 (Figure 19). It 
was able to inhibit extracellular release of IL-6 induced by IL I-p  and TN F-a but 
could not influence two of the main pathways involved in IL I-p  and TNF-a  
signaling.
W e further decided to measure the IL-6 cellular content when stimulated with 
IL I-P  and TN F-a and observe any possible effects of IL-10. First, we wanted to 
observe the time dependence of IL-6 stimulation mediated synergistically by IL1- 
P and TNF-a. Figure 20 represents the IL-6 synergistic accumulation by IL I-p  
and TNF-a. Interestingly, we observe the same amount of IL-6 after stimulation of 
1 , 2 , 4  and 6 h. Cellular IL-6 remained the same throughout the time treatment 
and suggested no dependence on time. W e further observed the effects of GABA 
and IL-10 on cellular IL-6 content stimulated by IL I-p  and TNF-a. Neither GABA
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nor IL-10 was able to reverse IL-6 accumulation at 4 and 6 hours. Furthermore, 
we see that both IL -ip  and TN F-a induced kB -a  degradation, although very 
slightly. No change was observed in kB -P  or P-actin, as expected (Figure 21). 
Since no difference in IL-6 stimulation was observed with 6 h of stimulation with 
cytokines, we decided to design an experiment where IL-6 accumulation was 
observed after overnight treatment with inflammatory cytokines. Again, we 
observed no change in IL-6 content even after 24 h. The inhibitor kB -a  was 
slightly degraded even after extended times. kB-P, P-actin and total p38 
remained unchanged as expected. Interestingly, IL -ip  and TN F-a induced 
phosphorylation in p38 at all time points. Moreover, IL-10 slightly reversed this 
effect at 2 and 4 hours compared to GABA (Figure 22). W e therefore decided to 
reduce the time frame for cytokine stimulation. C6 cells were stimulated for 15 
and 30 min with IL -ip  and TN F-a and effects of GABA, IL-10, IL-4 and 
SB203580 were observed. Intracellular IL-6, p-actin and p38 remained the 
same. However, phosphorylation of p38 was apparently reversed at 30 min by 
GABA, IL-10, IL-4 and SB203580 compared to 15 minutes treatments (Figure 
23). W e were not able to deduce with complete accuracy the optimal time frame 
for maximal p38 inhibition by IL-10 or any other anti-inflammatory cytokine. There 
are many variables in the experiments including cell split number or time of 
treatment when cells are most responsive.
Finally, we investigated the effects of IL-10 on IL-6 transcription. W e observed 
synergistic activation of IL-6 transcription induced by IL -ip  and TNF-a. IL-10 had 
no effect and was not able to reverse the stimulation and neither could GABA.
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SB203580 was a positive control and inhibited IL-6 transcription after stimulation 
with inflammatory cytokines (Figure 24). In addition, we decided to test another 
MAP kinase and its involvement in our pathway of investigation, c-Jun-N-terminal 
kinase (JNK). W e found that when phosphorylation of JNK is stimulated either 
with TNF-a or IL -ip , IL-10 reduced pJNK (Figures 25, 26). This suggests that 
inhibition of extracellular IL-6 release may be through a mechanism involving a 
MAP kinase. Results in this thesis and the research performed led us to propose 
a plausible point of inhibition by IL-10, represented by Figure 27.
These results suggested that IL-10 may be interfering at a post translational 
level with IL-6 transcript. There are two plausible locations where IL-10 can 
inhibit or prevent IL-6 from leaving the cell. One potential model for IL-10 
inhibition of IL-6 translation may be through interfering with the ribosomal 
assembly and thus reducing the amount of mature IL-6 transcript. Another model 
may be similar to the mode of action of brefeldin -  A (BFA), a drug that disrupts 
the Golgi apparatus and secretory mechanism. In mammals the target of BFA is 
the G TP/G DP exchange factor required for ARF (ADP-ribosylation factor) 
binding (Helms and Rothman, 1992;). BFA changes the structure of Golgi 
apparatus and block the transport of secretory proteins from the endoplasmic 
reticulum (ER) to the Golgi (Klausner et al., 1992). Therefore, IL-10 may be 
preventing glycosylation and formation of mature IL-6 from leaving the cell by 
interfering with the Golgi apparatus.
In summary, our results presented in this thesis show the synergistic effect of 
IL -ip  and TN F-a on the release of extracellular IL-6. W e also showed that both of
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these cytokines are able to stimulate and activate p38 and NF-kB signaling. 
Moreover, IL-10 may be involved in post-translational mechanism to prevent IL-6 
release based on the following: [1] IL-10 did not prevent the activation of p38 or 
NF-kB, [2] IL-10 did not reduce transcription of IL-6 [3] IL-10 showed no change 
in intracellular IL-6 levels after stimulation with IL -ip  and TN F-a  [4] IL-10 reduced 
phosphorylation of JNK, induced by TNF-a and IL -ip , suggesting a possible 
mechanism involving MAP kinase in inhibiting IL-6 release. IL-10 mechanism of 
action is very similar to that GABA, another inhibitory neurotransmitter in the 















Figure 1: Schematic representation of p38 and NF-kB signaling induced by IL-1P 
and TN F-a and possible IL-10 interference point.
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Figure 2: Effects of srotonin (5-HT) on IL -ip  signaling. Rat C6 cells were plated 
(3.0 X  10® cells/dish in a PDL-coated 35 X  10 mm-dishes). Cells were pretreated 
with lu M  of 5-HT and Im M  of Bu2cAMP for 1 hour and co-treated with lu M  of 5- 
HT, Im M  of Bu2cAMP and IL -ip  (50ng/ml) for 15 minutes. Post stimulation 
cellular protein was extracted and 25 pg of the total protein were subsequently 
separated via SDS-PAGE followed by Western analysis for total p38 and 
phosphorylated p38 protein (1:1000 for all). The data are represented as the 
observations obtained from a single experiment.
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Figure 3; Effects of concentration of 5-HT on IL -ip  signaling. Rat C6 ceils were 
plated (3.0 X10® cells/dish in a PDL-coated 35 X  10 mm-dishes). Cells were 
pretreated with lOOnM, 500nmM and Ip M  of 5-HT for 1 hour and co-treated with 
lOOnM, 500nmM and Ip M  of 5-HT and IL -ip  (50ng/ml) for 15 minutes. Post 
stimulation cellular protein was extracted and 25 pg of the total protein were 
subsequently separated via SDS-PAGE followed by Western analysis for total 
p38 and phosphorylated p38 protein (1:1000 for all). The data are represented as 
the observations obtained from a single experiment.
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Figure 4; Effects of other inhibitors/modulators on IL-13 mediated 
phosphorylation of p38. Rat C6 cells were plated (3.0 X10® cells/dish in a PDL- 
coated 35 X  10 mm-dishes). Cells were pretreated with Ip M  5-HT, lOOpM 
NE,250ng/ml Cholera Toxin and lOpM IPT for 1 hour and co-treated with Ip M  5- 
HT, lOOpM NE, 250ng/ml Cholera Toxin, lOpM IPT and IL -ip  (50ng/ml) for 15 
minutes. Post stimulation cellular protein was extracted and 25 pg of the total 
protein were subsequently separated via SDS-PAGE followed by Western 
analysis for total p38 and phosphorylated p38 protein (1:1000 for all). The data 
are represented as the observations obtained from a single experiment.
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Figure 5: Concentration response of IPT on IL -ip  mediated p38 signaling 
pathway. Rat C6 cells were plated (3.0 X10® cells/dish in a PDL-coated 35 X  10 
mm-dishes). Cells were pretreated with Ip M , lOpM and lOOpM IPT for 1 hour 
and co-treated with Ip M , lOpM and lOOpM IPT and IL -ip  (50ng/ml) for 15 
minutes. Post stimulation cellular protein was extracted and 25 pg of the total 
protein were subsequently separated via SDS-PAG E followed by Western 
analysis for total p38 and phosphorylated p38 protein (1:1000 for all). The data 
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Figure 6: Lipoic acid as an inhibitor of IL-1 mediated p38 pathway. Rat C6 cells 
were plated (3.0 X I 0® cells/dish in a PDL-coated 35 X  10 mm-dishes). Cells were 
pretreated with 0.5mM and Im M  lipoic acid for 1 hour and co-treated with 0.5mM  
and Im M  lipoic acid and IL-13 (50ng/ml) for 15 minutes. 0.4%  and 0.2%  EtOH 
control points were showed in order to exclude possible interference with cell 
death. Post stimulation cellular protein was extracted and 25 pg of the total 
protein were subsequently separated via SDS-PAG E followed by Western 
analysis for total p38 and phosphorylated p38 protein (1:1000 for all). The data 










Figure 7: Lipoic acid as an inhibitor of TNF-a mediated NF-kB pathway. Rat C6 
cells were plated (3.0 X10® cells/dish in a PDL-coated 35 X 10 mm-dishes). Cells 
were pretreated with 0.5mM and Im M  lipoic acid for 1 hour and co-treated with 
0.5mM and Im M  lipoic acid and IL -ip  (50ng/ml) for 15 minutes. Post stimulation 
cellular protein was extracted and 25 pg of the total protein were subsequently 
separated via SDS-PAGE followed by Western analysis for total p38 and 
phosphorylated p38 protein (1:1000 for all). The data are represented as the 


















- i — — — I— — — I— — — r
G GTI IL-10 ITI GITI
09
S
3 5 0  
3 0 0  -  
2 5 0  -  
2 0  0 -  
1 5 0  -  
1 0 0  -  




Tl GTI IL-10 ITI GITI
Figure 8: Effects of serum containing medium (Panel [A]) vs. serum free (Panel 
[B]) on IL -ip  and TN F-a mediated synergistic release of IL-6 in ELISA. Rat C6 
cells were plated (125 X 10® cells/well in a PDL-coated 96-well plate) and were 
pretreated with inhibitors (Im M  GABA, lOOng/ml IL-10) alone for 1h and co­
treated with inhibitors alone, 50ng/ml IL -ip  and lOOng/ml TN F-a for 24 hours. 
Post stimulation, conditioned medium was removed and assayed for IL-6 using 
Pierce ELISA according to the manufacturer’s specifications. T  = TNF-a, I = IL- 
ip , G = GABA, IL-10 = interleukin 10. The data are represented as mean ± 
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Figure 9: Effects of concentration of GABA and IL-10 on IL-ipand TN F-a  
mediated synergistic release of IL-6 in ELISA. Rat C6 cells were plated (125 X 
10® cells/well in a PDL-coated 96-well plate) and were pretreated with inhibitors 
(0.1, 0.5 and Im M  GABA, 10, 25, 50 and 100ng/ml IL-10) alone for 1h and co­
treated with inhibitors alone, 50ng/ml IL -ip  and 100ng/ml TN F-a for 24 hours. 
Post stimulation, conditioned medium was removed and assayed for IL-6 using 
Pierce ELISA according to the manufacturer’s specifications. T = TNF-a, I = IL- 
ip , G = GABA, IL-10 = interleukin 10. The data are represented as mean ± 
s.e.m. of triplicate observations obtained from a single representative 
experiment.
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Figure 10: Evaluation of extended dose response of IL-10 on IL-ipand TN F-a  
mediated synergistic release of IL-6 in ELISA. Rat C6 cells were plated (125 X 
10® cells/well in a PDL-coated 96-well plate) and were pretreated with inhibitors 
( Im M  GABA, 1, 2,10,25,50 and 100ng/ml IL-10) alone for 1h and co-treated with 
inhibitors alone, 50ng/ml IL -ip  and 100ng/ml TN F-a for 24 hours. Post 
stimulation, conditioned medium was removed and assayed for IL-6 using Pierce 
ELISA according to the manufacturer’s specifications. T  = TNF-a, I = IL -ip , G = 
GABA, IL-10 = interleukin 10. The data are represented as mean ± s.e.m. of 
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Figure 11: Effects of IL-4 vs. IL-10 and GABA on IL-10 on IL-ipand TN F-a  
mediated synergistic release of IL-6 in ELISA. Rat C6 cells were plated (125 X 
10® cells/well in a PDL-coated 96-well plate) and were pretreated with inhibitors 
( Im M  GABA, 100ng/ml IL-10, 100ng/ml IL-4, lOpM SB203580) alone for 1h and 
co-treated with inhibitors alone, 50ng/ml IL -ip  and 100ng/ml TN F-a for 24 hours. 
Post stimulation, conditioned medium was removed and assayed for IL-6 using 
Pierce ELISA according to the manufacturer’s specifications. T = TNF-a, I = IL- 
ip , G = GABA, IL-10 = interleukin 10, IL-4 = Interleukin 4, SB = SB 203580. The  
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Figure 12: Effects of IL-10 in serum containing medium vs. serum deficient 
medium on IL -ip  and TN F-a mediated NF-kB degradation and phosphorylation 
of p38. Rat C6 cells were plated (3.0 X I 0® cells/dish in a PDL-coated 35 X  10 
mm-dishes). Cells were pretreated with 100ng/ml IL-10 for 1 hour and co-treated 
with 100ng/ml IL-10 and IL -ip  (50ng/ml) and TN F-a for 15 minutes. Post 
stimulation cellular protein was extracted and 25 pg of the total protein were 
subsequently separated via SDS-PAGE followed by Western analysis for total 
p38 and phosphorylated p38 protein, kB -a  and kB -p. IL-6 and p-actin were 
obtained by stripping the membranes by blocking with non-fat milk overnight and 
then probing with primary and secondary antibodies (1:1000 for all). The data are 
represented as the observations obtained from a single experiment.
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Figure 13: Effects of GABA in serum vs. serum deficient medium on 
phosphorylation of p38. Rat C6 cells were plated (3.0 X I 0® cells/dish in a PDL- 
coated 35 X  10 mm-dishes). Cells were pretreated with 1 mM GABA for 1 hour 
and co-treated with 1 mM GABA, IL -ip  (50ng/ml) and TN F-a (100ng/ml) for 15 
minutes. Post stimulation cellular protein was extracted and 25 pg of the total 
protein were subsequently separated via SDS-PAGE followed by Western 
analysis for total p38 and phosphorylated p38 protein (1:1000 for all). The data 








Figure 14: Effects of GABA in serum vs. serum deficient medium on degradation 
of IkB inhibitor of NF-kB. Rat C6 cells were plated (3.0 X I 0® cells/dish in a PDL- 
coated 35 X  10 mm-dishes). Cells were pretreated with 1 mM GABA for 1 hour 
and co-treated with 1 mM GABA, IL-13 (50ng/ml) and TN F-a (100ng/ml) for 15 
minutes. Post stimulation cellular protein was extracted and 25 pg of the total 
protein were subsequently separated via SDS-PAGE followed by Western 
analysis for k B -a  and kB-|3 protein (1:1000 for all). The data are represented as 
the observations obtained from a single experiment.
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IL-1 (100ng/ml) - + - - - + - - -
IL-1 (SOng/ml) - - + - - - + - -
IL-1 (25ng/ml) - - - + - - + - -
IL-1 (lOng/ml) - - - - + - - + -
IL-10 (100ng/ml) - - - - - + + + + +
pp38
Figure 15: Effects of low concentration of IL-13 on p38 signaling pathway. Rat C6 
cells were plated (3.0 X I 0® cells/dish in a PDL-coated 35 X 10 mm-dishes). Cells 
were pretreated with 100ng/ml IL-10 for 1 hour and co-treated with 100ng/ml IL- 
10 and IL-13 (10 ng/ml, 25ng/ml, 50ng/ml and 100ng/ml) for 15 minutes. Post 
stimulation cellular protein was extracted and 25 pg of the total protein were 
subsequently separated via SDS-PAGE followed by Western analysis for total 
p38 and phosphorylated p38 protein (1:1000 for all). The data are represented as 
the observations obtained from a single experiment.
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Figure 16: Effects of IL-10 on TNF-a-mediated phosphorylation p38. Rat C6 cells 
were plated (3.0 X I 0® cells/dish in a PDL-coated 35 X  10 mm-dishes). Cells were 
pretreated with 100ng/ml IL-10 for 1 hour and co-treated with 100ng/ml IL-10 and 
TNF-a (10 ng/ml, 25ng/ml, 50ng/ml and 100ng/ml) for 15 minutes. Post 
stimulation cellular protein was extracted and 25 pg of the total protein were 
subsequently separated via SDS-PAGE followed by Western analysis for total 
p38 and phosphorylated p38 protein (1:1000 for all). The data are represented as 
the observations obtained from a single experiment.
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IL-1 (100ng/ml) - + - - - + - - - -
IL-1 (50ng/ml) - - + - - - + - - -
IL-1 (25ng/ml) - - - + - - - + - -
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Figure 17: Effects of low concentration of IL -ip  on NF-kB signaling pathway. Rat 
C6 cells were plated (3.0 X I 0® cells/dish in a PDL-coated 35 X  10 mm-dishes). 
Cells were pretreated with 100ng/ml IL-10 for 1 hour and co-treated with 
100ng/ml IL-10 and IL -ip  (10 ng/ml, 25ng/ml, 50ng/ml and 100ng/ml) for 15 
minutes. Post stimulation cellular protein was extracted and 25 pg of the total 
protein were subsequently separated via SDS-PAGE followed by Western 
analysis for IkB-o and IkB-P protein (1:1000 for all). The data are represented as 









Figure 18: Effects of low concentration of TN F-a on NF-kB signaling pathway. 
Rat C6 cells were plated (3.0 X I 0® cells/dish in a PDL-coated 35 X 10 mm- 
dishes). Cells were pretreated with 100ng/ml IL-10 for 1 hour and co-treated with 
100ng/ml IL-10 and TNF-a (10 ng/ml, 25ng/ml, 50ng/ml and 100ng/ml) for 15 
minutes. Post stimulation cellular protein was extracted and 25 pg of the total 
protein were subsequently separated via SDS-PAGE followed by Western 
analysis for kB -a  and kB-|3 protein (1:1000 for all). The data are represented as 







Figure 19; Effects of IL-4 vs. IL-10 on IL -ip  and TN F-a  signaling. Rat C6 cells 
were plated (3.0 X I 0® cells/dish in a PDL-coated 35 X 10 mm-dishes). Cells were 
pretreated with 100ng/ml IL-10 and IL-4 for 1 hour and co-treated with 100ng/ml 
IL-10, 100ng/ml IL-4 and TN F-a (100ng/ml) + IL -ip  (50ng/ml) for 15 minutes. 
Post stimulation cellular protein was extracted and 25 pg of the total protein were 
subsequently separated via SDS-PAGE followed by Western analysis for kB -a, 
IkB-P, total p38 and phosphorylated p38 protein (1:1000 for all). The data are 
represented as the observations obtained from a single experiment.
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Figure 20: Time dependence of IL-1P and TNF-a mediated synergistic release of 
intracellular IL-6 in Western blot. Rat C6 cells were plated (3.0 X10® cells/dish in 
a PDL-coated 35 X  10 mm-dishes). Cells were treated with TN F-a (lOOng/ml) 
and IL -ip  (50ng/ml) for 1 , 2 , 4  and 6 hours. Post stimulation cellular protein was 
extracted and 25 pg of the total protein was subsequently separated via SDS- 
PAGE followed by Western analysis for IL-6 (Cell Sciences) protein (1:1000 for 














Figure 21; Time dependence of IL -ip  and TNF-a mediated synergistic release of 
intracellular IL-6 of GABA vs. IL-10 in serum rich medium. Rat C6 cells were 
plated (3.0 X I 0® cells/dish in a PDL-coated 35 X 10 mm-dishes). Cells were 
pretreated with lOOng/ml IL-10 and Im M  GABA for 1 hour and co-treated with 
lOOng/ml IL-10, Im M  GABA and TN F-a (100ng/ml) + IL -ip  (50ng/ml) for 4 and 6 
hours. Post stimulation cellular protein was extracted and 25 pg of the total 
protein were subsequently separated via SDS-PAGE followed by Western 
analysis for kB -a , kB-p, p-Actin and IL-6 protein (1:1000 for all). The data are 
represented as the observations obtained from a single experiment.
63
2 hours 24 hours
TNF-a (100ng/m l) 









. -  - - : »  -4 





Figure 22: Extended time response of IL -ip  and TN F-a mediated synergistic 
release of intracellular IL-6. Effects of GABA and IL-10 on p38 and NF-kB 
pathways. Rat C6 cells were plated (3.0 X I 0® cells/dish in a PDL-coated 35 X 10 
mm-dishes). Cells were pretreated with 100ng/ml IL-10 and Im M  GABA for 1 
hour and co-treated with 100ng/ml IL-10, Im M  GABA and TN F-a (100ng/ml) + 
IL -ip  (50ng/ml) for 2, 4 and 24 hours. Post stimulation cellular protein was 
extracted and 25 pg of the total protein were subsequently separated via SDS- 
PAGE followed by Western analysis for p38, pp38, kB -a , kB-P, P-Actin and IL-6 
protein (1:1000 for all). The data are represented as the observations obtained 










Figure 23: Time dependence intracellular IL-6 release. Rat C6 cells were plated 
(3.0 X10® cells/dish in a PDL-coated 35 X 10 mm-dishes). Cells were pretreated 
with 100ng/ml IL-10, Im M  GABA, 100ng/ml IL-4 and lOpM SB203580 for 1 hour 
and co-treated with 100ng/ml IL-10, Im M  GABA and TN F-a (100ng/ml) + IL -ip  
(50ng/ml) for 4 and 6 hours. Post stimulation cellular protein was extracted and 
25 pg of the total protein were subsequently separated via SDS-PAGE followed 
by Western analysis for kB -a , kB-P, p-Actin and IL-6 protein (1:1000 for all). The 









Figure 24: Relative expression of IL-6 transcript in cells treated with GABA, IL-10, 
TN F-a and IL-1 p. Rat C6 cells were plated (3.0 X I 0® cells/dish in a PDL-coated 
35 X 10 mm-dishes). Cells were pretreated with 10Ong/ml IL-10 and Im M  GABA 
for 1 hour and co-treated with 10Ong/ml IL-10, Im M  GABA and TN F-a (1 OOng/ml) 
+ IL -ip  (50ng/ml) for 4 hours. Post stimulation cellular RNA was extracted and 1 
pg of total ENA extract were subsequently separated and analyzed via semi- 










Figure 25: Effects of IL-10 on TNF-a-m ediated phosphorylation of JNK. Rat C6 
cells were plated (3.0 X I 0® cells/dish in a PDL-coated 35 X 10 mm-dishes). Cells 
were pretreated with 10Ong/ml IL-10 for 1 hour and co-treated with 10Ong/ml IL- 
10 and TN F-a (100, 50, 25, lOng/ml) for 15 min. Post stimulation cellular protein 
was extracted and 25 pg of the total protein were subsequently separated via 
SDS-PAGE followed by Western analysis for pJNK and P-Actin (1:1000 for all). 





Figure 26: Effects of IL-10 on IL-ip-m ediated phosphorylation of JNK. Rat C6 
cells were plated (3.0 X I 0® cells/dish in a PDL-coated 35 X 10 mm-dishes). Cells 
were pretreated with 10Ong/ml IL-10 for 1 hour and co-treated with 10Ong/ml IL- 
10 and IL -ip  (100, 50, 25, lOng/ml) for 15 min. Post stimulation cellular protein 
was extracted and 25 pg of the total protein were subsequently separated via 
SDS-PAGE followed by Western analysis for pJNK and total JNK (1:1000 for all). 












Figure 27: Postulated mechanism of IL-10 interaction with TN F-a and IL -ip  
activation of JNK and p38 MAP kinases.
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